PC04.01 Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First Versus Osimertinib First)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.104
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PC04.02 Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2015English

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2020English

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

First-Line Gefitinib Bei Nachweis Aktivierender EGFR-Mutationen

Best Practice Onkologie
Oncology
2012English

P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Healthcare Resource Utilization and Costs Associated With Patients Prescribed Afatinib or Erlotinib as First-Line Therapy for EGFR Mutation-Positive NSCLC in the United States

Journal of Medical Economics
Health Policy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy